Cold chain for cell and gene therapies

An autologous cell therapy is a single, irreplaceable batch that must travel twice — from the patient to the manufacturing site and back — and cannot be re-made if it is lost. That asymmetry, not the hardware, is what makes this cold chain different. Long-term storage and warming-rate recrystallisation are covered on robotic biobanking and sample storage; this page is the shipping and administration leg.

Why −130 °C is the real line, and −80 °C is not

Freezing a cell suspension does not remove water; it separates it. Ice forms from pure water, so the remaining unfrozen fraction becomes progressively more concentrated in salts and cryoprotectant until it stops crystallising and thickens into a glass. The glass transition of these concentrated solutions lies near −130 °C. Above it the residual liquid still has molecular mobility, so ice crystals grow at the expense of smaller ones and solutes keep reacting — slowly, but without a floor. A −80 °C freezer therefore holds a product for weeks or months; it does not archive it. Below the glass transition, diffusion effectively ceases and storage time becomes indefinite, which is why the definitive formats are liquid-nitrogen vapour phase and dry vapour shippers charged with nitrogen absorbed into a porous matrix.

The two-factor injury, and what the freezing rate is for

Mazur’s two-factor hypothesis explains why controlled-rate freezing exists. Cool too slowly and extracellular ice concentrates the remaining solution; the cell dehydrates osmotically and is damaged by prolonged exposure to high solute concentration and by membrane collapse. Cool too quickly and water cannot leave fast enough, so it nucleates inside the cell, and intracellular ice is generally lethal. Survival therefore peaks at an intermediate rate, and the optimum is cell-type specific because it depends on membrane water permeability. A controlled-rate freezer also has to manage the latent heat released when the sample nucleates, which otherwise produces a temperature rebound; a deliberate cooling overshoot at that point keeps the excursion small and the nucleation uniform across the batch. USP General Chapter <1044> sets out cryopreservation practice for cells of this kind.

DMSO is a therapeutic problem, not only a formulation one

Dimethyl sulfoxide permeates the membrane and suppresses ice, and it is also cytotoxic — increasingly so above a few degrees Celsius and with time. A thawed product is therefore on a clock measured in minutes, and the choices at the bedside are to infuse promptly at the frozen concentration or to wash, accepting the cell loss that washing costs. Infused DMSO is itself associated with infusion reactions, so dose per kilogram is a clinical constraint on formulation volume.

Excursions accumulate

Because damage above the glass transition is rate-driven and irreversible, the meaningful record is not “did it stay in range” but the integrated time-above-temperature across every leg — pick-up, flight, customs hold, ward freezer. A shipper’s static hold time is the margin that record consumes. ISO 21973 addresses transport of cells for therapeutic use, and continuous logging with chain-of-identity linkage to the specific patient is what makes an excursion assessable rather than merely alarming.